studies

mNSCLC - L1 - PDL1 positive, Immune checkpoint association vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.79 [0.65; 0.96] KEYNOTE-598, 2020 1.08 [0.85; 1.37] MYSTIC (DT ; PDL1>25%), 2020 0.85 [0.61; 1.18] 0.90[0.73; 1.10]CheckMate 227 (NI vs C ; PDL1>1%), 2018, KEYNOTE-598, 2020, MYSTIC (DT ; PDL1>25%), 2020350%1,686moderatenot evaluable progression or deaths (PFS)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.82 [0.69; 0.97] KEYNOTE-598, 2020 1.06 [0.86; 1.30] MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.72; 1.53] 0.95[0.78; 1.14]CheckMate 227 (NI vs C ; PDL1>1%), 2018, KEYNOTE-598, 2020, MYSTIC (DT ; PDL1>25%), 2020350%1,686moderatenot evaluable objective responses (ORR)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 1.31 [0.97; 1.76] KEYNOTE-598, 2020 1.00 [0.72; 1.39] MYSTIC (DT ; PDL1>25%), 2020 0.87 [0.55; 1.37] 1.08[0.86; 1.37]CheckMate 227 (NI vs C ; PDL1>1%), 2018, KEYNOTE-598, 2020, MYSTIC (DT ; PDL1>25%), 2020324%1,686moderatenot evaluable AE (any grade)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 0.43 [0.15; 1.24] 0.43[0.15; 1.24]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable AE (grade 3-4)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 0.86 [0.56; 1.35] 0.86[0.56; 1.35]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable AE leading to death (grade 5)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 3.45 [1.24; 9.59] 3.45[1.24; 9.59]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 1.63 [0.91; 2.93] 1.63[0.91; 2.93]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable SAE (any grade)detailed resultsMYSTIC (DT ; PDL1>25%), 2020 1.93 [1.22; 3.04] 1.93[1.22; 3.04]MYSTIC (DT ; PDL1>25%), 202010%316NAnot evaluable STRAE (any grade)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 1.96 [1.36; 2.83] MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.59; 1.87] 1.50[0.82; 2.75]CheckMate 227 (NI vs C ; PDL1>1%), 2018, MYSTIC (DT ; PDL1>25%), 2020269%1,094moderatenot evaluable STRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 1.98 [1.32; 2.98] 1.98[1.32; 2.98]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable TRAE (any grade)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.66 [0.46; 0.94] MYSTIC (DT ; PDL1>25%), 2020 0.17 [0.09; 0.30] 0.34[0.09; 1.30]CheckMate 227 (NI vs C ; PDL1>1%), 2018, MYSTIC (DT ; PDL1>25%), 2020293%1,094moderatenot evaluable TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.96 [0.72; 1.29] MYSTIC (DT ; PDL1>25%), 2020 0.36 [0.22; 0.60] 0.60[0.23; 1.58]CheckMate 227 (NI vs C ; PDL1>1%), 2018, MYSTIC (DT ; PDL1>25%), 2020291%1,094moderatenot evaluable TRAE leading to death (grade 5)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.28; 3.45] MYSTIC (DT ; PDL1>25%), 2020 0.94 [0.06; 15.13] 0.98[0.31; 3.06]CheckMate 227 (NI vs C ; PDL1>1%), 2018, MYSTIC (DT ; PDL1>25%), 202020%1,094moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 3.13 [1.95; 5.03] MYSTIC (DT ; PDL1>25%), 2020 1.04 [0.54; 2.03] 1.85[0.63; 5.45]CheckMate 227 (NI vs C ; PDL1>1%), 2018, MYSTIC (DT ; PDL1>25%), 2020286%1,094moderatenot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 5.13 [2.63; 10.00] 5.13[2.63; 10.00]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.11 [0.04; 0.28] 0.11[0.04; 0.28]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 1.24 [0.33; 4.65] 1.24[0.33; 4.65]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.02; 50.01] 0.99[0.02; 50.01]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.25; 3.99] 0.99[0.25; 3.99]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 3.00 [0.60; 14.96] 3.00[0.60; 14.96]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 2.00 [0.60; 6.70] 2.00[0.60; 6.70]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.28 [0.06; 1.35] 0.28[0.06; 1.35]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.01 [0.00; 0.23] 0.01[0.00; 0.23]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 3.97 [0.18; 88.42] 3.97[0.18; 88.42]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 18.21 [1.05; 315.26] 18.21[1.05; 315.26]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.10 [0.01; 0.76] 0.10[0.01; 0.76]CheckMate 227 (NI vs C ; PDL1>1%), 201810%778NAnot evaluable Anaemia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.14 [0.41; 3.20] 1.14[0.41; 3.20]KEYNOTE-598, 202010%563NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.01 [0.36; 11.05] 2.01[0.36; 11.05]KEYNOTE-598, 202010%563NAnot evaluable Asthenia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.25 [0.03; 2.22] 0.25[0.03; 2.22]KEYNOTE-598, 202010%563NAnot evaluable Back pain AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.04; 5.51] 0.50[0.04; 5.51]KEYNOTE-598, 202010%563NAnot evaluable Constipation AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.00 [0.14; 7.12] 1.00[0.14; 7.12]KEYNOTE-598, 202010%563NAnot evaluable Cough AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.02; 14.89] 0.50[0.02; 14.89]KEYNOTE-598, 202010%563NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 6.03 [0.30; 120.98] 6.03[0.30; 120.98]KEYNOTE-598, 202010%563NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 10.29 [1.31; 80.96] 10.29[1.31; 80.96]KEYNOTE-598, 202010%563NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.87 [0.31; 2.43] 0.87[0.31; 2.43]KEYNOTE-598, 202010%563NAnot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.51 [0.42; 5.39] 1.51[0.42; 5.39]KEYNOTE-598, 202010%563NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.00 [0.06; 16.01] 1.00[0.06; 16.01]KEYNOTE-598, 202010%563NAnot evaluable Increase AST AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.52 [0.48; 13.09] 2.52[0.48; 13.09]KEYNOTE-598, 202010%563NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.28 [0.69; 7.50] 2.28[0.69; 7.50]KEYNOTE-598, 202010%563NAnot evaluable Nausea AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 4.01 [0.18; 89.26] 4.01[0.18; 89.26]KEYNOTE-598, 202010%563NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.36 [0.72; 2.56] 1.36[0.72; 2.56]KEYNOTE-598, 202010%563NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.21 [0.83; 5.91] 2.21[0.83; 5.91]KEYNOTE-598, 202010%563NAnot evaluable Pruritus AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.04; 5.51] 0.50[0.04; 5.51]KEYNOTE-598, 202010%563NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 6.03 [0.30; 120.98] 6.03[0.30; 120.98]KEYNOTE-598, 202010%563NAnot evaluable Rash AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 16.38 [0.94; 286.59] 16.38[0.94; 286.59]KEYNOTE-598, 202010%563NAnot evaluable Vomiting AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 4.03 [0.45; 36.27] 4.03[0.45; 36.27]KEYNOTE-598, 202010%563NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-05-14 02:23 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 171 - treatments: 856,634,861,416,864,769,980

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons